NCT00004890 is a Phase 1 clinical trial of aldesleukin in Drug Extravasation, sponsored by BioMedicines.

Who is sponsoring NCT00004890?

NCT00004890 is sponsored by BioMedicines.

What drugs are being tested in NCT00004890?

Interventions in NCT00004890: aldesleukin, Biomed 101.

What condition does NCT00004890 study?

NCT00004890 studies Drug Extravasation, Kidney Cancer.

Is NCT00004890 still recruiting?

NCT00004890 is currently completed. Last updated 25 March 2013.

Last reviewed 2013-03-25 · How we verify

NCT00004890

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy

Completed Phase 1 Last updated 25 March 2013

What this trial tests

Phase 1 trial testing aldesleukin in Drug Extravasation. Completed in 1 December 2002.

Timeline

1 December 2000

Primary endpoint
1 December 2002

1 December 2002

Quick facts

Lead sponsor	BioMedicines
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 December 2000
Primary completion	1 December 2002
Estimated completion	1 December 2002
Sites	1 location across United States

Drugs / interventions tested

aldesleukin (ALDESLEUKIN) — full drug profile →
Biomed 101 — full drug profile →

Conditions studied

Drug Extravasation — all drugs for Drug Extravasation →
Kidney Cancer — all drugs for Kidney Cancer →

Sponsor

BioMedicines — full company profile →

Who can join

18 and older, any sex, with Drug Extravasation or Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Biomed 101 may protect normal cells from the side effects of interleukin-2. PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients receiving interleukin-2 for kidney cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of aldesleukin

Trials testing the same drug.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT02316964 — Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid L · Phase 1 · completed
NCT02203604 — High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery · Phase 2 · terminated
NCT02070406 — Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignan · Phase 1 · terminated
NCT01700946 — Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00004890 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioMedicines
Last refreshed: 25 March 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00004890.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing